The pharmaceutical industry is bracing for significant changes as President Donald Trump announced a plan to impose 100% tariffs on imported generic drugs starting in August 2028. This bold move, aimed at reshoring pharmaceutical production to the United States, has sparked a wave of discussions and concerns about its potential impacts on drug prices and availability.
The announcement, made via a Truth Social post, outlines a phased approach: a 100% tariff will be imposed initially, followed by a 200% tariff one year later. The President’s objective, as stated, is to protect the people of the United States by encouraging pharmaceutical companies to establish production facilities within the country. However, the specifics of the penalties for non-compliance remain unclear.
Understanding the Generic Drug Market
Generic drugs are medications that contain the same active ingredients as their brand-name counterparts but are typically sold at significantly lower prices. According to research by Robin Feldman a professor at the University of California Law San Francisco the average price of a generic drug is just $4, compared to $157 for brand-name drugs after rebates. These drugs account for more than 90% of prescriptions filled in the U.S., making them a critical component of the healthcare system.
Over the past decade, the production of generic drugs has increasingly shifted to other countries, with India and China emerging as the leading suppliers. This shift has raised national security concerns, as highlighted by a 2026 report from the Senate Committee on Aging. The report found that India supplies roughly half of the generic drugs in the U.S., and about 80% of the active pharmaceutical ingredients used by Indian manufacturers are supplied by China. Additionally, a 2026 report from the Coalition for a Prosperous America revealed that China accounts for about 95% of imports of ibuprofen and 70% of imports of acetaminophen.
Potential Impacts on Consumers and the Industry
The proposed tariffs could have far-reaching consequences for consumers and the pharmaceutical industry. While generic drugs are significantly cheaper than their brand-name counterparts, the imposition of tariffs could still lead to price increases. Merith Basey CEO of Patients For Affordable Drugs expressed concern that imposing massive tariffs on generic medicines risks making lower-cost generic drugs millions of Americans rely on more expensive and harder to access.
Experts also worry that high tariffs may lead to a shortage of some generic drugs in the U.S., if manufacturers decide to leave the American market entirely. The rising cost of health care is already a major concern for many Americans, with recent polling indicating that nearly 50% of adults find it hard to afford these costs. Moreover, more than 40% of adults have not taken medication prescribed by their provider in the past 12 months due to high costs.
The industry’s response to the proposed tariffs remains to be seen. John Murphy III president and CEO of the Association for Accessible Medicines stated that his organization needs to better understand the terms of the policy. He emphasized the need for policies that support and stabilize both the industry and the access necessary to ensure patients have reliable options for affordable medicines.
The Shift to Domestic Manufacturing
Bringing generic drug production back to the U.S. would likely raise drug prices in the short term. The U.S. has more than 1,400 manufacturing sites designed to finish medications into pills, capsules, or liquid vials. However, only 230 U.S. factories make active pharmaceutical ingredients, compared to 524 in China, 564 in India, and 670 in Europe. This disparity highlights the challenges of reshoring pharmaceutical production.
Additionally, ingredients for nearly half of the drugs designated as essential medicines by the Department of Health and Human Services are made domestically. However, U.S. sites do not produce ingredients for 40 of 83 essential medicines, according to data from QYOBO, a drug intelligence platform. This underscores the complexity of the supply chain and the potential impacts of the proposed tariffs.
